ArticleBiotechnology and bioengineering2010
High-level rapid production of full-size monoclonal antibodies in plants by a single-vector DNA replicon system.
Article in Biotechnology and bioengineering, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
98 citing papers in PubMed, 191 citations in OpenAlex.
- Plant-Based Systems for Producing Therapeutic Proteins: Current Status and Future Prospects.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- The landscape of antibody production systems: recombinant expression for research, diagnostics and therapy.Frontiers in bioengineering and biotechnology · 2026Review
- Engineering Conditional Transgene Expression in Nicotiana benthamiana.Plant biotechnology journal · 2026Review
- Bioluminescence-Driven Optimization of Geminivirus-Based Vectors as Tools for Plant Biotechnology.ACS synthetic biology · 2025Article
- Efficient production of functional cholera toxin B subunit using geminiviral replicons inFrontiers in bioengineering and biotechnology · 2025Article
- High-Level Production of a Recombinant Protein inInternational journal of molecular sciences · 2024Article
- Reversible female contraceptives: historical, current, and future perspectives†.Biology of reproduction · 2024Review
- High production of recombinant protein using geminivirus-based deconstructed vectors inFrontiers in plant science · 2024Article
- In vitro and in vivo studies of plant-produced Atezolizumab as a potential immunotherapeutic antibody.Scientific reports · 2023Article
- Review
- Apoplastic Production of Recombinant AntiVEGF Protein Using Plant-Virus Transient Expression Vector.Molecular biotechnology · 2022Article
- Current Status and Perspective on the Use of Viral-Based Vectors in Eukaryotic Microalgae.Marine drugs · 2022Review
- Development of a plant-produced recombinant monoclonal antibody against Δ-9-tetrahydrocannabinol (Δ9-THC) for immunoassay application.Biotechnology reports (Amsterdam, Netherlands) · 2022Article
- Development of plant-made monoclonal antibodies against viral infections.Current opinion in virology · 2022Review
- Improving Protein Quantity and Quality-The Next Level of Plant Molecular Farming.International journal of molecular sciences · 2022Review
- Construction of SARS-CoV-2 virus-like particles in plant.Scientific reports · 2022Article
- Plant-Based Vaccines: Antigen Design, Diversity, and Strategies for High Level Production.Vaccines · 2022Review
- Geminivirus-Derived Vectors as Tools for Functional Genomics.Frontiers in microbiology · 2022Review
- Feasibility of plant-expression system for production of recombinant anti-human IgE: An alternative production platform for therapeutic monoclonal antibodies.Frontiers in plant science · 2022Article
- Review
38 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
Plant viral vectors have great potential in rapid production of important pharmaceutical proteins. However, high-yield production of hetero-oligomeric proteins that require the expression and assembly of two or more protein subunits often suffers problems due to the "competing" nature of viral vectors derived from the same virus. Previously we reported that a bean yellow dwarf virus (BeYDV)-derived, three-component DNA replicon system allows rapid production of single recombinant proteins in plants (Huang et al., 2009. Biotechnol Bioeng 103: 706-714). In this article, we report further development of this expression system for its application in high-yield production of oligomeric protein complexes including monoclonal antibodies (mAbs) in plants. We showed that the BeYDV replicon system permits simultaneous efficient replication of two DNA replicons and thus, high-level accumulation of two recombinant proteins in the same plant cell. We also demonstrated that a single vector that contains multiple replicon cassettes was as efficient as the three-component system in driving the expression of two distinct proteins. Using either the non-competing, three-vector system or the multi-replicon single vector, we produced both the heavy and light chain subunits of a protective IgG mAb 6D8 against Ebola virus GP1 (Wilson et al., 2000. Science 287: 1664-1666) at 0.5 mg of mAb per gram leaf fresh weight within 4 days post-infiltration of Nicotiana benthamiana leaves. We further demonstrated that full-size tetrameric IgG complex containing two heavy and two light chains was efficiently assembled and readily purified, and retained its functionality in specific binding to inactivated Ebola virus. Thus, our single-vector replicon system provides high-yield production capacity for hetero-oligomeric proteins, yet eliminates the difficult task of identifying non-competing virus and the need for co-infection of multiple expression modules. The multi-replicon vector represents a significant advance in transient expression technology for antibody production in plants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.